Clinical trials: Malignant Hemopathy
Malignant Hemopathy
Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation
Description of the evolution of the biological characteristics of immune blood populations and biomarkers of interest in patients who have received allogeneic hematopoietic stem cell transplantation.
- Trial name
- SIA-CSH (NCT03965429)
- Testing
- Blood samples (additional tubes from care) longitudinal, Blood samples (additional tubes from care) at inclusion
- Where
- France
- Volunteers
- 1,020 people
- Sponsor
- Institut Paoli-Calmettes
Hematologic Malignancies, Thrombopenia
Interpretability of the Quantra® Viscoelastic Test in Patients With Haematological Malignancies With Profound Thrombocytopenia Below 50x10 G/L.
The goal of this single-center, non-controlled, non-randomized exploratory clinical trial is to evaluate the interpretability of viscoelastic tests (Quantra® and ROTEM® type) in relation to platelet levels measured in standard…
- Trial name
- VISCOTHEM-1 (NCT06455553)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Centre Hospitalier Annecy Genevois
Malignant Hemopathy, Duration of Neutropenia Following Chemotherapy > 10 Days
Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia
Empirical antifungal treatment is the gold standard for patients who are neutropenic and have persistent fever under broad-spectrum antibiotics.
- Trial name
- NCT00190463
- Testing
- Amphotericin B
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Malignant Hemopathy
Characteristics and Results of Patients Treated by Therapeutic Intensification
Many studies have focused on patients treated with allogeneic peripheral stem cell transplantation; few studies have until now been carried out to describe the characteristics and results of autografted patients and to attempt to…
- Trial name
- AutoREA (NCT06894381)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Strasbourg, France
Chronic Coronary Syndrome, Heart Failure
COVID-19 Related Lockdown Effects On Chronic Diseases
The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation.
- Conditions
- Chronic Coronary Syndrome, Heart Failure, AMD and Macular Edema, Chronic Respiratory Failure
- Trial name
- CLEO-CD (NCT04390126)
- Testing
- life questionnaires, questionnaire
- Where
- France
- Volunteers
- 1,343 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Bone Metastasis, Malignant Hemopathy
Validation of Radio-induced Damage Biomarkers
The aim of this study is to confirm in humans the relevance and the kinetics of radio-induced bio-markers in plasma and urines, previously described at the preclinical stage.
- Trial name
- BIOM-DRI (NCT02999152)
- Testing
- blood and urines samples
- Where
- 2 sites in France
- Volunteers
- 16 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Leukemia, Lymphoma
RAT-HEMATO : Return to Work After Malignant Hemopathy
Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- RAT-HEMATO (NCT06262789)
- Testing
- "Return-to-work after cancer" consultation
- Where
- 10 sites in France
- Volunteers
- 264 people
- Sponsor
- University Hospital, Angers
Solid Tumors, Malignant Hemopathy
Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents
The main aim of the study is to assess the safety of Nivestim® treatment in patients treated with neutropenia-inducing chemotherapy for a malignant disease, solid tumor or a malignant hemopathy.
- Conditions
- Solid Tumors, Malignant Hemopathy, Chemotherapy-induced Febrile Neutropenia (FN)
- Trial name
- NCT01574235
- Testing
- Nivestim®
- Where
- 87 sites in France
- Volunteers
- 2,114 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Myeloablative Allo-SCT
Randomized, Prospective, Multicenter Study to Compare Enteral Nutrition to Parenteral Nutrition as Feeding Support in Patients Presenting Malignant Hemopathy Who Underwent an Allogeneic Hematopoietic Stem Cell Transplantation.
Myeloablative allogeneic hematopoetic stem cell transplantation (AHSCT) are prone to frequent secondary malnutrition to metabolic and digestive troubles due to conditioning regimen, treatments (antibiotics, immunosuppressive…
- Trial name
- NEPHA (NCT01955772)
- Testing
- Enteral nutrition alanyl-glutamin, Dipeptiven
- Where
- France
- Volunteers
- 240 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hematologic Cancer
Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance
The main objective is to study the genomic, transcriptomic, proteomic epigenomic, metabolomic and immune mechanisms of blasts and microenvironment cells associated with IT resistance through the constitution of a collection…
- Trial name
- NCT05602168
- Testing
- experimental:Acute leukemia/myelodysplastic or myeloproliferative disease
- Volunteers
- 400 people
- Sponsor
- Institut Paoli-Calmettes
Malignant Hemopathy
Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells
Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite of medical improvement, some of these pathologies present drug resistances, or high risk of relapse.
- Trial name
- MENTALO (NCT04517656)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne